Alpha Tau Medical (DRTS) Income towards Parent Company (2021 - 2026)
Alpha Tau Medical (DRTS) posted Income towards Parent Company of $22.9 million for Q1 2026, up 87.93% sequentially from $12.2 million in Q4 2025, and up 166.98% YoY from $8.6 million in Q1 2025.
Analysis
Alpha Tau Medical (DRTS) Income towards Parent Company (2021 - 2026) Analysis & Trends
Alpha Tau Medical has reported Income towards Parent Company for 6 years, with the latest figure at $22.9 million in Q1 2026.
- Quarterly Income towards Parent Company rose 166.98% year-over-year to $22.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.8 million (up 75.67% YoY) and the FY2025 annual result came in at $42.4 million, up 33.55% from the prior year.
- Income towards Parent Company improved to $22.9 million in Q1 2026 per DRTS's latest filing, from $12.2 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $25.7 million in Q1 2022 and troughed at $2.0 million in Q2 2022.
- A 5-year average of $9.4 million and a median of $8.1 million in 2023 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2022 and 2023: Income towards Parent Company sank 71.42% in 2022, then soared 334.88% in 2023.
- Over 5 years, Income towards Parent Company stood at $3.4 million in 2022, then soared by 116.78% to $7.3 million in 2023, then advanced by 28.89% to $9.5 million in 2024, then advanced by 28.86% to $12.2 million in 2025, then soared by 87.93% to $22.9 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered $22.9 million, $12.2 million, and $11.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Alpha Tau Medical | 1.21 Bn | 1.11 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 45.36 Mn |
| Mar 31, 2026 | 22.96 Mn |
| Dec 31, 2025 | 12.21 Mn |
| Sep 30, 2025 | 11.70 Mn |
| Jun 30, 2025 | 9.98 Mn |
| Mar 31, 2025 | 8.49 Mn |
| Dec 31, 2024 | 9.47 Mn |
| Sep 30, 2024 | 6.92 Mn |
| Jun 30, 2024 | 7.36 Mn |
| Mar 31, 2024 | 7.98 Mn |
| Dec 31, 2023 | 7.35 Mn |
| Sep 30, 2023 | 4.99 Mn |
| Jun 30, 2023 | 8.64 Mn |
| Mar 31, 2023 | 8.15 Mn |
| Dec 31, 2022 | 3.39 Mn |
| Sep 30, 2022 | 2.61 Mn |
| Jun 30, 2022 | 1.99 Mn |
| Mar 31, 2022 | 25.74 Mn |
| Dec 31, 2021 | 3.81 Mn |
| Sep 30, 2021 | 4.81 Mn |